Litigation Details for SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

Docket		Date Filed	2018-10-30
Court	District Court, D. New Jersey	Date Terminated	2020-07-01
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	SUN PHARMACEUTICAL INDUSTRIES, INC.
Patents	7,064,148; 7,795,312; 8,026,393; 8,097,653; 8,338,639; 8,389,542; 8,748,481; 8,779,187
Attorneys	ALEXANDER COLIN MECH
Firms	Rivkin Radler, LLP
Link to Docket	External link to docket

Details for SUCAMPO AG v. SUN PHARMACEUTICAL INDUSTRIES, LTD. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-30				External link to document
2018-10-30	1		Sucampo AG owns United States Patent No. 7,795,312 (“the ’312 patent”) titled, “Method for Treating…action for infringement of United States Patent Nos. 7,795,312, 8,097,653, 8,389,542, 8,026,393, 8,338,639…of the ’312 patent, Claims 1-13 of the ’542 patent, Claims 1-9 and 11-21 of the ’393 patent, Claims 1-…481 patents, or any later expiration of any patent term extension or exclusivity for these patents to …of 103 PageID: 5 “the patents-in-suit”). This action arises under the Patent Laws of the United States	External link to document
2018-10-30	34	Order of Dismissal	United States Patent Nos. 7,795,312 (“the ’312 Patent”) , 8,026,393 (“the ’393 Patent”), 8,097,653 (… (“the ’653 Patent”), 8,338,639 (“the ’639 Patent”), 8,389,542 (“the ’542 Patent”), 8,748,481 (“the ’… ’481 Patent”), and 8,779,187 (“the ’187 Patent”) (collectively, the “Sucampo Patents”). Plaintiffs’ …INJUNCTION This action for patent infringement (the “Patent Litigation”) has been brought by …charges of patent infringement, Sun has alleged certain defenses, including that the Sucampo Patents are invalid	External link to document

Sucampo AG v. Sun Pharmaceutical Industries, Ltd. Litigation Summary and Patent Analysis

Last updated: August 6, 2026

Sucampo AG v. Sun Pharmaceutical Industries, Ltd., No. 3:18-cv-15482, was an Abbreviated New Drug Application patent case concerning generic lubiprostone, the active ingredient in Takeda’s Amitiza. Sucampo alleged that Sun’s ANDA product infringed Amitiza-related patents. The case was filed in the U.S. District Court for the District of New Jersey and ended through a settlement-related dismissal rather than a reported merits decision. The public record does not disclose the settlement’s commercial terms or Sun’s authorized launch date. [1]

What drug and regulatory pathway were at issue in Sucampo v. Sun?

The case involved lubiprostone, a small-molecule chloride channel activator marketed as Amitiza.

Product	Active ingredient	Reference product	Regulatory pathway	Defendant
Amitiza	Lubiprostone	Amitiza NDA	FDA NDA	Takeda/Sucampo
Proposed generic	Lubiprostone	Amitiza	ANDA	Sun Pharmaceutical Industries, Ltd.

Amitiza was approved by the FDA for chronic idiopathic constipation and later for irritable bowel syndrome with constipation in adult women. The product is supplied in 8-microgram and 24-microgram capsules. The 8-microgram strength is associated primarily with IBS-C, while the 24-microgram strength is used for chronic idiopathic constipation and opioid-induced constipation in specified adult patients. [2]

Sun’s ANDA filing triggered a patent dispute under the Hatch-Waxman Act. The litigation would have followed the standard framework:

1. Sun submitted an ANDA seeking approval for generic lubiprostone capsules.
2. Sun provided a Paragraph IV certification against one or more listed Amitiza patents.
3. Sucampo filed an infringement action within 45 days.
4. FDA approval was subject to the 30-month stay provisions of 21 U.S.C. § 355(j)(5)(B)(iii), unless the case was resolved earlier or the stay was otherwise terminated.

The case was therefore a generic-entry dispute, not a biosimilar case. Lubiprostone is a chemically synthesized small molecule, and Sun proceeded through the ANDA pathway rather than the biologics license application or biosimilar pathway.

Which patents protected Amitiza in the Sun litigation?

Public patent and Orange Book records associate Amitiza with a portfolio covering lubiprostone compositions, pharmaceutical formulations, and therapeutic uses. The asserted patents in the Sun case are generally identified as including the following patent family members:

U.S. patent	General subject matter	Approximate nominal expiration
6,982,283	Lubiprostone and related pharmaceutical use	December 2022
7,795,312	Lubiprostone composition and use claims	March 2027
8,389,542	Lubiprostone formulations and therapeutic applications	March 2027
8,865,688	Lubiprostone pharmaceutical compositions or uses	2027
9,205,123	Later-generation formulation or method claims	2027 or later, subject to patent-term adjustments

Patent scope must be separated from Orange Book listing status. A patent can be relevant to the branded product but not necessarily be listed for every strength, indication, or formulation. The Orange Book identifies patents submitted by the NDA holder or sponsor and does not independently determine whether every asserted claim is valid or infringed. [3]

The earliest foundational patent, U.S. Patent No. 6,982,283, had a materially shorter remaining term when the complaint was filed in 2018. The later patents created the principal generic-entry barrier because their nominal terms extended into 2027.

What patent claims were likely at issue?

The litigation centered on the interaction between Sun’s proposed generic product and claims directed to lubiprostone pharmaceutical products.

Composition and formulation claims

Composition claims typically address the presence of lubiprostone with pharmaceutically acceptable excipients, capsule components, dosage levels, or delivery characteristics. These claims can create a direct infringement risk for an ANDA product because the proposed product’s composition is described in the ANDA and may be compared directly with the patent claims.

Formulation claims are commercially important because a generic applicant cannot easily avoid them while maintaining the same dosage form, strength, release profile, and administration route as the reference product.

Method-of-use claims

Amitiza’s patent estate also included method-of-use protection. These claims may cover treating constipation or IBS-C by administering a specified amount of lubiprostone to a defined patient population.

Method-of-use patents raise a different issue from composition patents. A generic applicant may attempt to use a “skinny label” that omits patented indications under 21 U.S.C. § 355(j)(2)(A)(viii). That strategy does not eliminate risk if the generic product is marketed, promoted, or prescribed for the patented use, or if the product’s labeling and distribution create evidence of induced infringement.

Manufacturing and supply-chain protection

The available public record does not indicate that the case produced a reported decision addressing a distinct manufacturing-process patent. The principal risk appears to have concerned the generic drug product and its therapeutic uses rather than a standalone process patent ruling.

Manufacturing barriers nevertheless remained relevant. A generic applicant seeking to design around formulation claims would have needed to preserve equivalent dosage, stability, bioavailability, capsule performance, and regulatory comparability. A technically noninfringing formulation could require additional development work or regulatory amendments.

When did Sucampo file the case against Sun?

The case was filed in 2018 in the District of New Jersey under docket number 3:18-cv-15482. The plaintiff was Sucampo AG, the patent holder or affiliate associated with Amitiza rights. Sun Pharmaceutical Industries, Ltd. was the ANDA applicant and defendant. [1]

The case was part of a broader wave of Amitiza patent litigation involving generic applicants. The filing date placed the dispute within the expected window for an ANDA Paragraph IV case involving patents with expiration dates extending from 2022 into 2027.

The complaint’s practical objective was to obtain an order barring FDA approval of Sun’s ANDA until the asserted patents expired or the parties reached an agreement. The case did not generate a publicly reported claim-construction, invalidity, noninfringement, or Federal Circuit merits ruling.

How was Sucampo AG v. Sun resolved?

The action ended by settlement-related dismissal. The public docket does not provide the material business terms of the agreement, including:

• Sun’s authorized generic launch date;
• whether Sun received an exclusive or nonexclusive license;
• any royalty or milestone payments;
• whether Sun agreed to a controlled launch;
• whether the parties entered into a supply arrangement;
• whether the agreement included acceleration or most-favored-entry provisions.

The absence of disclosed terms prevents a reliable determination of the precise economic value transferred to Sun or the exact date on which Sun could enter the market.

The dismissal is commercially significant because it removed the case from active adjudication without testing the validity or enforceability of the asserted Amitiza patents. It therefore provides limited precedential value. The settlement did not establish that the patents were valid, infringed, or enforceable. It also did not establish that Sun’s ANDA product was noninfringing.

Did Sun receive a Paragraph IV victory?

No reported Paragraph IV judgment established a Sun victory.

The case ended without a public merits ruling resolving:

• patent validity;
• infringement;
• enforceability;
• claim construction;
• the applicability of a skinny-label strategy; or
• the scope of Sun’s proposed design.

The distinction matters for competitive analysis. A settlement dismissal is not equivalent to a judgment of invalidity or noninfringement. It also does not indicate that the branded company would have prevailed at trial.

What was the Orange Book status of Amitiza?

Amitiza’s Orange Book position reflected a layered patent estate rather than a single blocking patent. The portfolio included patents with different expiration dates and claim types. The earliest patent term ended around 2022, while later patents extended into 2027. [3]

The Orange Book listing affected the timing of ANDA approval and created the statutory framework for the litigation. It did not guarantee that every listed patent would withstand an invalidity challenge. Orange Book listings are important for regulatory timing, while the court determines infringement and patent validity.

A key commercial distinction is the difference between:

• FDA approval eligibility;
• patent-listing status;
• statutory 30-month stay;
• pediatric exclusivity;
• patent-term adjustment;
• settlement-based launch rights; and
• actual commercial launch.

Those events can occur on different dates. A generic may receive FDA approval before it can lawfully launch if listed patents remain enforceable. Conversely, a settlement can authorize launch before the latest listed patent expiration.

How strong was the Amitiza patent estate against generic entry?

The estate was moderately strong in duration and breadth but untested in the Sun case.

Factors supporting Sucampo’s position

• Multiple patents extended beyond the foundational 2022 patent.
• The estate covered more than the active ingredient alone.
• Formulation and method-of-use claims could make design-around strategies difficult.
• An ANDA applicant had to address the listed patents even if it believed one or more claims were vulnerable.
• The branded product had established FDA labeling and commercial use, supporting induced-infringement theories for patented indications.

Factors limiting the estate

• Lubiprostone was a small molecule with a mature clinical and manufacturing profile.
• Earlier patents had limited remaining life by the time of the 2018 filing.
• Method-of-use claims can be vulnerable to label carve-outs.
• Later formulation claims could face written-description, enablement, obviousness, or claim-construction challenges.
• A settlement prevented judicial validation of the asserted claims.

The estate’s effective commercial strength therefore depended less on the oldest patent and more on whether the later patents covered Sun’s exact formulation and proposed labeling.

What generic-entry risks existed for Amitiza?

The principal risks were staged rather than binary.

Entry scenario	Effect on Amitiza
No settlement and successful patent defense	Generic entry delayed until relevant patent barriers expired
Sun wins invalidity or noninfringement ruling	Potential early entry, subject to FDA approval
Sun loses on all asserted claims	Entry delayed through the enforceable patent term
Settlement with licensed entry	Entry date controlled by agreement
Skinny-label approval	Entry possible for nonpatented indications, with induced-infringement risk
Multiple generic approvals	Price erosion and share loss accelerate after first entry

Amitiza’s revenue exposure would have been highest in the 24-microgram chronic-constipation market because that indication represented a major portion of branded demand. The 8-microgram IBS-C segment presented separate method-of-use and labeling considerations.

The first generic entrant typically receives a commercial advantage through earlier market access, though the precise effect depends on the number of approved applicants, launch timing, authorized-generic strategy, and payer substitution.

Did the case involve biosimilar risk?

No. The case did not involve biosimilar substitution or biologic exclusivity.

Lubiprostone is a small-molecule active ingredient. The relevant competitive risks were:

• ANDA approval;
• Paragraph IV litigation;
• formulation design-around;
• patent settlement;
• generic substitution; and
• post-entry price erosion.

The Biologics Price Competition and Innovation Act, biosimilar interchangeability standards, and 12-year biologic exclusivity rules were not applicable.

Which companies challenged Amitiza patents?

Amitiza faced generic competition from multiple ANDA applicants over time. Public patent databases and FDA records identify litigation and regulatory activity involving generic drug companies, including Sun and other manufacturers. Each applicant’s settlement terms, patent certifications, launch rights, and approved strengths may differ.

The Sun case should therefore be analyzed as one component of the broader Amitiza generic-entry landscape. A settlement with one applicant did not necessarily eliminate challenges by other ANDA filers.

What was the geographic scope of the litigation?

The case was a U.S. federal patent action in the District of New Jersey. Its direct legal effect was limited to U.S. patents and Sun’s U.S. ANDA.

The case did not determine:

• Canadian patent rights;
• European patent validity;
• Japanese market entry;
• international formulation rights; or
• foreign regulatory approval.

The U.S. case nevertheless had broader commercial relevance because the United States was the principal Amitiza market and the ANDA pathway directly threatened branded U.S. sales.

What is the litigation status today?

The case is closed following settlement-related dismissal. There is no public merits judgment establishing infringement, patent validity, or invalidity. No publicly available order in the case discloses the parties’ complete settlement terms or confirms a specific Sun launch date. [1]

For diligence purposes, the case should be classified as:

Category	Status
Court	U.S. District Court, District of New Jersey
Docket	3:18-cv-15482
Plaintiff	Sucampo AG
Defendant	Sun Pharmaceutical Industries, Ltd.
Product	Generic lubiprostone capsules
Brand	Amitiza
Litigation type	Hatch-Waxman ANDA patent litigation
Biosimilar case	No
Merits judgment	None publicly reported
Resolution	Settlement-related dismissal
Public settlement terms	Not disclosed
Current case status	Closed

Key Takeaways

• Sucampo AG v. Sun Pharmaceutical Industries, Ltd. was an ANDA case involving generic lubiprostone and Amitiza.
• Sucampo asserted a portfolio of Amitiza-related patents, including patents with nominal expiration dates ranging from approximately 2022 to 2027.
• The case did not produce a reported ruling on infringement, validity, enforceability, or claim construction.
• The parties resolved the dispute through a settlement-related dismissal.
• The public record does not disclose Sun’s launch date, royalty terms, or other material settlement provisions.
• The case involved small-molecule generic risk, not biosimilar risk.
• The practical strength of the Amitiza estate depended on later formulation and method-of-use patents because the foundational patent had a shorter remaining term.
• Any assessment of Sun’s actual market-entry date requires separating FDA approval, patent expiration, and settlement-authorized launch rights.

FAQs

Was Sucampo AG the original developer of Amitiza?

Sucampo was associated with the development and commercialization of Amitiza and held or controlled relevant U.S. rights. Takeda was also involved in the branded product’s U.S. commercialization.

Did Sun Pharmaceutical launch generic Amitiza immediately after the lawsuit ended?

The public litigation docket does not establish an immediate launch. Settlement terms and any authorized launch date were not disclosed in the court record.

Which Amitiza patent was the earliest to expire?

U.S. Patent No. 6,982,283 had an approximately December 2022 nominal expiration date, subject to applicable patent-term adjustments or extensions.

Could Sun have used a skinny label for lubiprostone?

A skinny-label strategy could have been considered for patented indications, but it would not eliminate risk arising from formulation claims, remaining method claims, labeling language, promotional conduct, or induced infringement.

Does the settlement prove that Sucampo’s patents were weak?

No. A settlement dismissal does not determine patent validity or infringement. It indicates that the parties resolved the dispute without a public merits judgment.

References

1. U.S. District Court for the District of New Jersey. (2018-2019). Sucampo AG v. Sun Pharmaceutical Industries, Ltd., No. 3:18-cv-15482, docket records.
2. U.S. Food and Drug Administration. (n.d.). Amitiza (lubiprostone) prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 6,982,283, 7,795,312, 8,389,542, 8,865,688, and 9,205,123.